Search Result
Results for "
antituberculosis
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-146055
-
|
Bacterial
|
Infection
|
Antituberculosis agent-1 (Compound 8a) is an antituberculosis agent with an MIC of 3.84 µg/mL against M. tuberculosis H37Rv .
|
-
-
- HY-146057
-
|
Bacterial
|
Infection
|
Antituberculosis agent-2 (Compound 8d) is an antituberculosis agent against agent-sensitive and multidrug-resistant tuberculosis. Antituberculosis agent-2 shows anti-tuberculosis activity with MIC values of 0.454, 1.757 and 1.644 μg/mL against M. tuberculosis H37Rv, 13946 and 14862, respectively. Antituberculosis agent-2 displays favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability .
|
-
-
- HY-151205
-
|
Bacterial
|
Infection
Inflammation/Immunology
|
Antituberculosis agent-3 (Compound 2) is an antituberculosis agent. Antituberculosis agent-3 shows anti-mycobacterial activity, and can inhibit M. tuberculosis H37Rv strain growth (MIC=12.5 μg/mL) .
|
-
-
- HY-152136
-
|
Bacterial
Fungal
|
Infection
|
Antituberculosis agent-6 (compound 9g) is a potent antimycobacterial agent. Antituberculosis agent-6 shows significant activity against M. tuberculosis, with a MIC of 3.49 μM. Antituberculosis agent-6 also shows good antifungal activity against A. niger, with a MIC of 62.50 μM. Antituberculosis agent-6 shows high GI absorption .
|
-
-
- HY-152137
-
|
Bacterial
Fungal
Antibiotic
|
Infection
Inflammation/Immunology
|
Antituberculosis agent-7, an oxetanyl-quinoline derivative, has shown good antibacterial activity against P. mirabilis with a MIC of 31.25 μM. Antituberculosis agent-7 shows good antifungal activity against A. niger with a MIC of 62.5 μM. Antituberculosis agent-7 shows excellent antimycobacterial activity with MIC 3.41 μM for M. tuberculosis H37Rv .
|
-
-
- HY-151514
-
|
Bacterial
|
Infection
|
Antituberculosis agent-5 (compound 52) is a nitrofuranylamide derivative, inhibits M. tuberculosis UDP-Gal mutase. Antituberculosis agent-5 inhibits Glf activity with an IC50 value of 99 μM/mL and resists tuberculosis (TB) with a MIC value of 1.6 μg/mL .
|
-
-
- HY-152138
-
|
Bacterial
Fungal
|
Infection
|
Antituberculosis agent-8 (Compound 9i) is an antitubercular agent with an MIC of 3.53 μM (1.6 μg/mL) against M. tuberculosis H37Rv. Antituberculosis agent-8 also shows good antifungal activity against A. niger with an MIC of 62.50 μM .
|
-
-
- HY-149064
-
|
Bacterial
|
Infection
|
Antituberculosis agent-9 (Compound 5a) is an orally active antitubercular agent with an MIC of 0.5 μg/mL against H37Ra .
|
-
-
- HY-100531
-
|
Bacterial
|
Infection
|
DprE1-IN-2 (compound 18) is a potent DprE1 inhibitor with an IC50 of 28 nM. DprE1-IN-2 has antituberculosis effect .
|
-
-
- HY-156412
-
|
Bacterial
|
Infection
|
DHFR-IN-10 (compound 4c) is a potent DHFR inhibitor, with an IC50 of 4.21 μM for M. tuberculosis DHFR enzyme. DHFR-IN-10 exhibits potent antituberculosis efficiency .
|
-
-
- HY-134940
-
OPC-167832
|
Bacterial
|
Infection
Inflammation/Immunology
|
Quabodepistat (OPC-167832) is a potent and orally active dprE1 inhibitor with an IC50 of 0.258 μM. Quabodepistat has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis .
|
-
-
- HY-12903
-
PBTZ169
|
Bacterial
Antibiotic
|
Infection
|
Macozinone (PBTZ169) is a bactericidal benzothiazinone and a potent DprE1 (decaprenylphosphoryl-β-d-ribose 2′-oxidase) inhibitor. Macozinone inhibits the essential flavoprotein DprE1 by forming a covalent bond with the active-site Cys387 residue. Macozinone has antituberculosis effect .
|
-
-
- HY-155558
-
|
Antibiotic
|
Infection
|
MptpB-IN-2 (compound 20) is a selective mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with IC50s of 0.64 μM, 4.06 μM and 4.14 μM for MptpB, MptpA and PTP1B, respectively. MptpB-IN-2 shows weak antituberculosis activity with a MIC of 64.9 μM for Mtb H37Rv .
|
-
-
- HY-B1040
-
-
-
- HY-W716673
-
-
-
- HY-139695
-
|
Bacterial
|
Infection
|
Spectinamide-1599 is a combination partner for anti-tuberculosis research.
|
-
-
- HY-14990
-
LL 3858
|
Bacterial
|
Infection
|
Sudoterb (LL 3858) is an orally active anti-Tuberculosis agent .
|
-
-
- HY-14990A
-
LL 3858 hydrochloride
|
Bacterial
|
Infection
|
Sudoterb (LL 3858) hydrochloride is an orally active anti-Tuberculosis agent .
|
-
-
- HY-112091
-
|
Bacterial
|
Infection
|
GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.
|
-
-
- HY-76210
-
-
-
- HY-W039897
-
-
-
- HY-153009
-
|
Bacterial
|
Infection
|
MMV676584 has anti-tuberculosis avtivity. MMV676584 is a novel agent candidate for eumycetoma .
|
-
-
- HY-148478
-
(R)-GSK1729177A
|
DNA/RNA Synthesis
|
Infection
|
MMV688845 is a nontuberculous mycobacteria (NTM) RNA polymerase inhibitor with bactericidal activity against Mycobacterium abscessus and anti-tuberculosis efficacy .
|
-
-
- HY-12485
-
|
Bacterial
Antibiotic
|
Infection
|
TBA-354 is a potent anti-tuberculosis compound; maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains.
|
-
-
- HY-142031
-
|
Bacterial
|
Infection
|
4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNA synthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent .
|
-
-
- HY-139863
-
|
Bacterial
|
Infection
|
Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.
|
-
-
- HY-146348
-
|
Bacterial
|
Infection
|
Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue without noticeable cytotoxicity. Tuberculosis inhibitor 5 is an anti-tuberculosis agent .
|
-
-
- HY-126131
-
|
Bacterial
|
Infection
|
anti-TB agent 1 is a potent and orally active anti-tuberculosis agent, with MICs of < 2 nM against the Mtb strains H37Rv, rRMP and rINH .
|
-
-
- HY-128866
-
|
Bacterial
|
Infection
|
TBAJ-876 is the inhibitor of mycobacterium tuberculosis. TBAJ-876 is the analogue of the anti-tuberculosis agent Bedaquiline. TBAJ-876 has the potential for the research of tuberculosis .
|
-
-
- HY-W028047
-
|
Bacterial
|
Infection
Inflammation/Immunology
|
JFD01307SC is a glutamine synthetase inhibitor and anti-tuberculosis agent. JFD01307SC acts as a mimic of L-Glutamate and thus target enzymes involved in glutamine biosynthesis .
|
-
-
- HY-126597
-
|
Bacterial
|
Infection
|
Chaetoglobosin C (Compound 4) is a anthraquinone-chromone compound derived from the fungus Chaetomium globosum KMITL-N0802. Chaetoglobosin C has anti-tuberculosis activity .
|
-
-
- HY-19750
-
|
Bacterial
|
Infection
|
TBA-7371 is a potent, noncovalent DprE1 inhibitor. TBA-7371 has potent antitubercular activity .
|
-
-
- HY-N0872
-
(-)-Isosteviol; iso-Steviol
|
Reactive Oxygen Species
Topoisomerase
|
Cardiovascular Disease
Cancer
|
Isosteviol ((-)-Isosteviol) is a derivative of Stevioside through acid catalyzed hydrolysis of Stevioside. Isosteviol inhibits DNA polymerase and DNA topoisomerase and has antibacterial, anticancer and anti-tuberculosis effects .
|
-
-
- HY-155067
-
|
Bacterial
|
Infection
|
Antitubercular agent-38 is an orally active Benzothiazinones (BTZs) derivate, with potent antituberculosis activity. Antitubercular agent-38 exhibits low cardiac toxicity, low cell cytotoxicity .
|
-
-
- HY-148564
-
|
Bacterial
|
Infection
|
TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) .
|
-
-
- HY-162028
-
|
Bacterial
|
Infection
|
GaMF1.39 is an antimycobacterial compound, targeting the F-ATP synthase subunit γ. GaMF1.39 displays enhanced anti-tuberculosis activity in combination with ETC inhibitors .
|
-
-
- HY-162094
-
|
Bacterial
|
Infection
|
Antitubercular agent-44 (compound 21b) has anti-tuberculosis (H37Rv MIC = 0.06 μM). Antitubercular agent-44 has oral activity .
|
-
-
- HY-N8388
-
|
Bacterial
|
Infection
|
Collinin is a anti-tubercular agent, it can be isolated from leaves of Z. schinifolium. Collinin has an excellent anti-tuberculosis effect against multidrug-resistant (MDR), extensively drug-resistant (XDR) strains .
|
-
-
- HY-W018677S
-
|
Antibiotic
|
Infection
|
Quinoxaline-d4 is the deuterium labeled Quinoxaline[1]. Quinoxaline is a chemical compound that acts as an intermediate for anti-tuberculosis agent Pyrazinamide. Quinoxaline presents a structure that is similar to quinolone antibiotics[2].
|
-
-
- HY-151956
-
|
Bacterial
|
Infection
|
Mtb-cyt-bd oxidase-IN-7 is a cytochrome bd terminal oxidase (Cyt-bd) inhibitor with a Kd value of 4.17 μM. Mtb-cyt-bd oxidase-IN-7 shows anti-tuberculosis activities .
|
-
-
- HY-163107
-
|
Bacterial
|
Infection
|
Antimycobacterial agent-7 (compound 4) is a 1,2,4-triazole anti-tuberculosis agent (MIC: 2 μg/mL). Antimycobacterial agent-7 inhibits Mtb KatG and causes the accumulation of ROS in Mtb cells. ROS produces oxidative damage, leading to the death of Mtb .
|
-
-
- HY-150967
-
|
Bacterial
|
Infection
|
MmpL3-IN-1 (compound 32) is a potent Mycobacterial membrane protein large 3 (MmpL3) inhibitor. MmpL3-IN-1 has anti-tuberculosis activity with the MIC<0.016 μg/mL in M. tuberculosis and can be used in studies of drug-resistant tuberculosis .
|
-
-
- HY-117145
-
|
Bacterial
|
Infection
|
Thiophene-2 (TP2) is a specific polyketide synthase 13 (Pks13) inhibitor. Thiophene-2 inhibits mycolic acid biosynthesis and rapidly leads to mycobacterial cell death. Thiophene-2 is active against Mycobacterium tuberculosis with a MIC value of 1 μM, and has potent anti-tuberculosis activity .
|
-
-
- HY-111747
-
|
Bacterial
|
Infection
Cardiovascular Disease
|
TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and <0.02 µg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization .
|
-
-
- HY-122643
-
|
Bacterial
|
Infection
|
NITD-916, a 4-hydroxy-2-pyridone derivative, is an orally active and highly lipophilic mycobacterial enoyl reductase InhA inhibitor with an IC50 of 570 nM. NITD-916 forms a ternary complex with InhA and NADH to block access to the fatty acyl substrate binding pocket. NITD-916 has potent anti-tuberculosis effects .
|
-
-
- HY-146158
-
|
Bacterial
Potassium Channel
Antibiotic
|
Infection
|
WX-081, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. WX-081 exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for agent susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. WX-081 also inhibits hERG channel with the IC50 of 1.89 μM.
|
-
-
- HY-14743B
-
SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride
|
Bacterial
STAT
|
Infection
Inflammation/Immunology
Cancer
|
Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride (SCV 07 hydrochloride) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod hydrochloride (SCV 07 hydrochloride) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .
|
-
-
- HY-145286
-
|
Bacterial
|
Infection
Cancer
|
IMPDH2-IN-2 is a potent inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH) with a Ki,app value of 14 μM, respectively. IMPDH2-IN-2 displays moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively). IMPDH2-IN-2 is a potential anti-tuberculosis agent .
|
-
-
- HY-14743
-
SCV 07; Gamma-D-glutamyl-L-tryptophan
|
Bacterial
STAT
|
Infection
Inflammation/Immunology
Cancer
|
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .
|
-
-
- HY-14743A
-
SCV 07 TFA; Gamma-D-glutamyl-L-tryptophan TFA
|
Bacterial
STAT
|
Infection
Inflammation/Immunology
Cancer
|
Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .
|
-
- HY-151598
-
|
Bacterial
|
Infection
|
Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC50=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .
|
-
- HY-151599
-
|
Bacterial
|
Infection
|
Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC50=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .
|
-
- HY-13588
-
SCE-129 sodium
|
Bacterial
Antibiotic
|
Infection
|
Cefsulodin (SCE-129) sodium is a third generation β lactam antibiotic and member of the cephems subgroup of antibiotics. Cefsulodin sodium inhibits cell wall synthesis by competitively inhibiting penicillin binding protein (PBP) cross-linking and transpeptidation of peptidogly. Cefsulodin sodium is a potent tyrosine phosphatase inhibitor against mPTPB, a virulent phosphatase from Mycobacterium tuberculosis, with an IC50 value of 16 μM .
|
-
-
-
HY-L142
-
|
94 compounds
|
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.
Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.
MCE supplies a unique collection of 94 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-14743
-
SCV 07; Gamma-D-glutamyl-L-tryptophan
|
Bacterial
STAT
|
Infection
Inflammation/Immunology
Cancer
|
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W018677S
-
|
Quinoxaline-d4 is the deuterium labeled Quinoxaline[1]. Quinoxaline is a chemical compound that acts as an intermediate for anti-tuberculosis agent Pyrazinamide. Quinoxaline presents a structure that is similar to quinolone antibiotics[2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: